Investors have circled back to healthcare stocks this year, and they’re likely to stick around. If they came for the ...

The success of Eli Lilly’s Zepbound, a challenger to Novo’s Wegovy, has prompted comparisons to a similar scenario, when ...

Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.

The diet and weight-loss brand, which has struggled to adapt in the Ozempic era, is losing its latest chief executive after ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...

On Thursday, Eli Lilly And Co (LLY) stock saw a decline, ending the day at $909.32 which represents a decrease of $-15.24 or -1.65% from the prior close of $924.56. The stock opened at $920.26 and ...

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term ...

BioAge Labs stock rose Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity treatments.

Hundreds of Americans have jumped on a multi-state lawsuit alleging that the makers of Ozempic and Mounjaro caused ...

Zacks Eli Lilly's Early Alzheimer's Treatment Donanemab Scores Japanese Approval, Its Second Largest Market Eli Lilly's Kisunla (donanemab) has been approved in Japan for early symptomatic ...